Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,581.3
-14.7 (-0.56%)

 

  • STI Straits Times Index
    2,581.3
    -14.7 (-0.56%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,564.6
    -11.8 (-0.75%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,183.0
    -47.7 (-0.19%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,360.1
    39.4 (1.19%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,289.4
    39.8 (0.17%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,247.7
    8.4 (0.16%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,818.9M
  • Value: 1,195.1M
  • Rise: 145
  • Fall: 205
  • Unch: 458

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.036-
Yinda Infocomm0.035-
Rex Intl0.168-0.013
ChinaKundaTech0.028+0.002
FJ Benjamin^0.020+0.002
Singapore-eDev0.062-0.012
Medtecs Intl1.610+0.050
ThaiBev0.605-
Kitchen Culture0.215-0.105
AnAn Intl0.037-

World Indices

World Indices
Name Last Change
Nasdaq 9,757.2 -259.8
HSI 24,253.8 -296.2
HSCEI 9,745.8 -107.4
Jakarta 4,863.1 -41.0
Nikkei 225 22,064.8 -447.3
SSE Comp 2,959.0 -11.7
Shanghai A 3,101.5 -12.2
Shanghai B 211.6 -1.8
KOSPI 2,100.4 -34.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 14 Aug 2020 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 12.08577 Trailing EPS (SGD) e 15.90599 NAV (SGD) b 127.5600
PE a 6.617 Trailing PE f 5.028 Price / NAV b 0.6269
Dividend (SGD) d 3.825784 Cash In Hand (SGD) g 10.9782 Issued & Paid-up Shares c 74,289,000
Dividend Yield (%) d 4.784 Price / Cash In Hand g 7.284 Treasury Shares h 180,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,940.891
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,813.749
Piotroski F Score 8 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 27 Jul 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Jul 2020.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,940.891 6.617 5.028 0.6269 4.784
Industry Biotechnology SGX 2,986.920 6.654 5.056 0.6293 4.758
Foreign Listing (Others) SGX 9,127.035 71.648 62.228 2.3192 2.039
Medical & Biotechnology SGX 949.910 20.889 19.246 1.3354 2.022
Local Peer Suntar Eco-City SGX 32.949 6562.500 6589.682 1.9098 -
Global Peer AMGEN INC NASDAQ 140,835.979 17.959 19.295 13.2129 2.436
Global Peer CSL ASX 126,834.048 47.275 43.784 14.6656 0.950
Global Peer GILEAD SCIENCES INC NASDAQ 85,478.630 15.871 - 4.7417 3.732
Global Peer AMGEN-T HKEx 585,694.000 9.532 10.295 7.0897 4.589
Global Peer VERTEX PHARMACEUTICAL NASDAQ 69,583.759 59.129 33.441 9.2541 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 64,993.791 30.718 21.784 7.1758 -
Global Peer ILLUMINA INC NASDAQ 51,615.380 51.512 74.481 11.3117 -
Global Peer BIOGEN INC NASDAQ 45,679.633 7.757 7.707 4.0393 -
Global Peer WUXI BIO HKEx 216,907.105 188.686 188.685 15.1677 -
Global Peer SEATTLE GENETICS INC NASDAQ 27,863.880 - - 15.3598 -
Other Global Peers MODERNA INC (NASDAQ), ALEXION PHARMACEUTICAL INC (NASDAQ), SINO BIOPHARM (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), INCYTE CORPORATION (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NOVAVAX INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), EXELIXIS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GENSCRIPT BIO (HKEx), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), FATE THERAPEUTICS (NASDAQ), ALKERMES PLC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), INSMED INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), HAOHAI BIOTEC (HKEx), ALLOVIR INC (NASDAQ), VAXCYTE INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIELA BIO INC (NASDAQ), VERACYTE INC (NASDAQ), ALPHAMAB-B (HKEx), XENCOR INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), AKEBIA THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), NANOSTRING TECHNOLOGIES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), COMPUGEN (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MESOBLAST LTD (ASX), COHERUS BIOSCIENCES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), ARVINAS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ASCENTAGE-B (HKEx), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), NANTKWEST INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), FRONTAGE (HKEx), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), NKARTA INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), OMEROS CORP (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PERSONALIS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), KINTOR PHARMA-B (HKEx), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECIGEN INC (NASDAQ), KADMON HLDGS INC (NYSE), AKOUOS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), AGENUS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), IMMATICS N V (NASDAQ), VANDA PHARMACE INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), GERON CORP (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PROTHENA CORP PLC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ARDELYX INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), DPHARMA (Bursa), XBIOTECH INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), ATHERSYS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SINOMAB BIO-B (HKEx), LEE'S PHARM (HKEx), CLOVIS ONCOLOGY INC (NASDAQ), ASCLETIS-B (HKEx), RIGEL PHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), IVERIC BIO INC (NASDAQ), KAMADA (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MERUS B V (NASDAQ), ESSEX BIO-TECH (HKEx), MANNKIND CORPORATION (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), NANOVIRICIDES INC (NYSE American), TREVENA INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), CONCERT PHARMACEUTICALS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), PFENEX INC (NYSE American), CALITHERA BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CABALETTA BIO INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), AFFIMED N V (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), VERASTEM INC (NASDAQ), NEXTCURE INC (NASDAQ), MEDICINOVA INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IBIO INC (NYSE American), EVOFEM BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), TELIX PHARMACEUTIC (ASX), CASI PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), XOMA CORP (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ADURO BIOTECH INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHIMERIX INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), FIVE PRIME THERAPEUTICS (NASDAQ), IMUGENE LIMITED (ASX), VTV THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), CONTRAFECT CORP (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), INMUNE BIO INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), ORGENESIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SESEN BIO INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), CEL-SCI CORP (NYSE American), ENZO BIOCHEM INC (NYSE), CHAMPIONS ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFLARX N V (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), UNI-BIO GROUP (HKEx), BIONANO GENOMICS INC (NASDAQ), SAVARA INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), AIM IMMUNOTECH INC (NYSE American), DIAMEDICA THERAPEUTICS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ARAVIVE INC (NASDAQ), VACCINEX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), RESTORBIO INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), GENOCEA BIOSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), MEMPHASYS LTD (ASX), RECRO PHARMA INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), COHBAR INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), ANTEOTECH LIMITED (ASX), MONOPAR THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), IMMUTEP LTD (ASX), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), VASCULAR BIOGENICS LTD (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), KAZIA THERAPEUTICS LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), BIOTRON (ASX), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ORAGENICS INC (NYSE American), SEELOS THERAPEUTICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), CT ENTERPRISE (HKEx), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIONOMICS LTD (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), EVOGENE LTD (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ADVAXIS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), BIOSINO BIO-TEC (HKEx), AETERNA ZENTARIS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), BIOCARDIA INC (NASDAQ), REGENEUS LTD (ASX), AZURRX BIOPHARMA INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), ADALTA LTD (ASX), RHINOMED LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), PATRYS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), SENECA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), REXAHN PHARMACEUTICALS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), SENESTECH INC (NASDAQ), CRYOSITE (ASX), HAO WEN HLDGS (HKEx), AURIS MEDICAL HOLDING LTD (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), LEAF RESOURCES LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), NANOLLOSE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(0.15 MB)
Part 2(18.45 MB)
Annual Report 2018 Dec 2018 Part 1(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
14 Aug 2020 79.970 79.970 79.970 79.970 - -
13 Aug 2020 79.970 79.970 79.970 79.970 - -
12 Aug 2020 79.970 79.970 79.970 79.970 - -
11 Aug 2020 79.970 79.970 79.970 79.970 - -
07 Aug 2020 79.970 79.970 79.970 79.970 - -
06 Aug 2020 79.970 79.970 79.970 79.970 - -
05 Aug 2020 79.970 79.970 79.970 79.970 - -
04 Aug 2020 79.970 79.970 79.970 79.970 - -
03 Aug 2020 79.970 79.970 79.970 79.970 - -
30 Jul 2020 79.970 79.970 79.970 79.970 - -
29 Jul 2020 79.970 79.970 79.970 79.970 - -
28 Jul 2020 79.970 79.970 79.970 79.970 - -
27 Jul 2020 79.970 79.970 79.970 79.970 - -
24 Jul 2020 79.970 79.970 79.970 79.970 - -
23 Jul 2020 79.970 79.970 79.970 79.970 - -
22 Jul 2020 79.970 79.970 79.970 79.970 - -
21 Jul 2020 79.970 79.970 79.970 79.970 - -
20 Jul 2020 79.970 79.970 79.970 79.970 - -
17 Jul 2020 79.970 79.970 79.970 79.970 - -
16 Jul 2020 79.970 79.970 79.970 79.970 - -
15 Jul 2020 79.970 79.970 79.970 79.970 - -
14 Jul 2020 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(30 Jul 2020 to 14 Aug 2020)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(16 Jul 2020 to 29 Jul 2020)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(17 Jun 2020 to 15 Jul 2020)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.